Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for anti-hyperlipidemic efficacy

Current Drug Delivery

Volumn 13, Issue 2, 2016, Pages 211-220

  Kurakula, Mallesh ^a   Ahmed, Tarek A ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

Atorvastatin; Hypolipidemic efficacy; In situ gel; Nanocrystals; PLGA

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ATORVASTATIN; BENZYL BENZOATE; CHITOSAN; NANOCRYSTAL; POLYGLACTIN; DRUG CARRIER; GEL; HYPOCHOLESTEROLEMIC AGENT; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; GEL; GELATION; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; X RAY POWDER DIFFRACTION; CHEMISTRY; HYPERLIPIDEMIAS; MEDICINAL CHEMISTRY; SURFACE PROPERTY; X RAY DIFFRACTION;

ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; DRUG LIBERATION; GELS; HYPERLIPIDEMIAS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLVENTS; SURFACE PROPERTIES; X-RAY DIFFRACTION;

EID: 84966431256     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201813666151109102718     Document Type: Article

References (38)

1. Packhaeuser, C.B., Schnieders, J., Oster, C.G., Kissel, T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. [Internet]. 2004 [cited 2015 Jan 22], 58, 445-55.
2. Kempe, S., Mäder, K. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J. Control. Release [Internet]. 2012 [cited 2015 Apr 2];161: 668-79.
3. Ahmed, T.A., Ibrahim, H.M., Ibrahim, F., Samy, A.M., Kaseem, A., Nutan, M.T.H., Hussain, M.D. Development of Biodegradable In Situ Implant and Microparticle Injectable Formulations for Sustained Delivery of Haloperidol. J. Pharm. Sci., 2012, 101,3753-62.
4. Fogueri, L.R., Singh, S. Smart polymers for controlled delivery of proteins and peptides: a review of patents. Recent Pat. Drug Deliv. Formul., 2009, 3, 40-8.
5. Ahmed, T.A. Approaches to develop PLGA based in situ gelling system with low initial burst. Pak. J. Pharm. Sci., 2015, 28, 657-65.
6. Chen, S., Singh, J. Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation. Int. J. Pharm., 2005, 295, 183-90.
7. Ahmed, T.A., Ibrahim, H.M., Samy, A.M., Kaseem, A., Nutan, M.T.H., Hussain, M.D. Biodegradable Injectable In Situ Implants and Microparticles for Sustained Release of Montelukast: In Vitro Release, Pharmacokinetics, and Stability. AAPS PharmSciTech., 2014, 15, 772-80.
8. Hatefi, A., Amsden, B. Biodegradable injectable in situ forming drug delivery systems. J. Control. Release, 2002, 80,9-28.
9. Kranz, H., Bodmeier, R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm., 2007, 332,107-14.
10. Merkli, A., Tabatabay, C., Gurny, R., Heller, J. Biodegradable polymers for the controlled release of ocular drugs. Prog. Polym. Sci., 1998, 23, 563-80.
11. Fredenberg, S., Wahlgren, M., Reslow., M., Axelsson, A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. Int. J. Pharm., 2011, 415, 34-52.
12. Graham, P., Brodbeck, K., McHugh, A. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control. Release 1999, 58, 233-45.
13. Tang, Y., Singh, J. Controlled delivery of aspirin: effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems. Int. J. Pharm., 2008, 357, 119-25.
14. Brodbeck KJ, Pushpala S, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm. Res., 1999, 16, 1825-9.
15. Raman, C., McHugh, A.J. A model for drug release from fast phase inverting injectable solutions. J. Control. Release, 2015, 102, 145-57.
16. Ibrahim, H.M., Ahmed, T., Hussain, M.D., Rahman, Z., Samy, A.M., Kaseem, A., Nutan, M.T. Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev. Ind. Pharm., 2013, 9045, 1-8.
17. Göpferich, A. Mechanisms of polymer degradation and erosion. Biomaterial. 1996, 17,103-14.
18. Dhawan, S., Kapil, R., Kapoor, D.N. Development and evaluation of in situ gel-forming system for sustained delivery of insulin. J. Biomater. Appl., 2011, 25, 699-720.
19. Junghanns, J.U.H., Müller, R.H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed., 2008, 3, 295-309.
20. Keck, C.M., Müller, R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm., 2006, 62, 3-16.
21. Kurakula, M., El-Helw, A.M., Sobahi, T.R., Abdelaal, M.Y. Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy. Int. J. Nanomed., 2015, 10, 321-34.
22. Kurakula, M., Sobahi, T.R., El-Helw, A.M., Abdelaal, M.Y. Development and Validation of a RP-HPLC Method for Assay of Atorvastatin and its Application in Dissolution Studies on Thermosensitive Hydrogel-Based Nanocrystals. Trop. J. Pharm. Res., 2014, 13, 1681-7.
23. Xin, C., Lihong, W., Qiuyuan L, Hongzhuo L. Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation. Int. J. Pharm., 2014, 469, 23-30.
24. Chaudhary, H.R., Brocks, D.R. The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines. J. Pharm. Pharm. Sci., 2013, 16, 65-73.
25. Kim, M., Kim, J., Cho, W., Park, H, Hwang S. Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers. Int. J. Biol. Macromol., 2013, 59, 138-42.
26. Ikoba, U., Peng, H., Li, H., Miller, C., Yu, C., Wang, Q. Nanocarriers in therapy of infectious and inflammatory diseases. Nanoscale Royal Soc. Chem., 2015, 7, 4291-305.
27. Al-Subaie, M.M., Hosny, K.M., Mohamed, El-Say, K., Ahmed,T., Aljaeid, B.M. Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. Int. J. Nanomed., 2015, 10, 3973-85.
28. Song, F., Li X, Wang Q, Liao L, Zhang C. Nanocomposite Hydrogels and Their Applications in Drug Delivery and Tissue Engineering. J. Biomed. Nanotechnol., 2015, 11, 40-52.
29. Wang, Q., Gu, Z., Jamal, S., Detamore, M.S., Berkland, C. Hybrid hydroxyapatite nanoparticle colloidal gels are injectable fillers for bone tissue engineering. Tissue Eng. Part A, 2013, 19, 2586-93.
30. Wang, Q., Jamal, S., Detamore, M.S., Berkland, C. PLGAchitosan/ PLGA-alginate nanoparticle blends as biodegradable colloidal gels for seeding human umbilical cord mesenchymal stem cells. J. Biomed. Mater. Res., 2011, 96, 520-7.
31. Wang, Q., Wang, L., Detamore, M.S., Berkland, C. Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds. Adv. Mater., 2008, 20, 236-9.
32. Ahmed, T.A., El-Say, K.M. Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole. Life Sci., 2014, 110, 35-43.
33. Burckbuchler, V., Mekhloufi, G., Giteau, P., Grossiord, J.L., Huille, S, Agnely, F. Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions. Eur. J. Pharm. Biopharm., 2010, 76, 351-6.
34. Husmann, M., Schenderlein, S., Lück, M., Lindner, H., Kleinebudde, P. Polymer erosion in PLGA microparticles produced by phase separation method. Int. J. Pharm., 2002, 242, 277-80.
35. Kadu, P.J., Kushare, S.S., Thacker, D.D., Gattani, S.G. Enhancement of oral bioavailability of atorvastatin calcium by selfemulsifying drug delivery systems (SEDDS). Pharm. Dev. Technol., 2011, 16, 65-74.
36. Choudhary, A., Rana, A.C., Aggarwal, G., Kumar, V., Zakir, F. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharm. Sin. B., 2012, 2, 421-8.
37. Maurya, D., Belgamwar, V., Tekade, A. Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. J. Pharm. Pharmacol., 2010, 62, 1599-606.
38. Vukkum, P., Moses, B. J., Muralikrishna, R. Stress Degradation Behavior of Atorvastatin Calcium and Development of a Suitable Stability-Indicating LC Method for the Determination of Atorvastatin, its Related Impurities, and its Degradation Products. Sci. Pharm., 2013, 81, 93-114.